Summary:
In patients undergoing coronary artery bypass grafting (CABG) or aortic valve replacement (AVR),
the glucagon-like peptide-1 (GLP-1) agonist exenatide administered during cardiopulmonary bypass and weaning did not significantly reduce the incidence of death, stroke, renal failure, or new/worsening heart failure compared to standard care without GLP-1 agonist intervention.
It was, however, not associated with any additional severe side effects.
| PICO | Description |
|---|---|
| Population | Adult patients undergoing coronary artery bypass grafting (CABG) or aortic valve replacement (AVR). |
| Intervention | Administration of the glucagon-like peptide-1 (GLP-1) agonist exenatide during cardiopulmonary bypass and weaning. |
| Comparison | Standard care without any GLP-1 agonist intervention. |
| Outcome | Exenatide did not significantly lower the incidence of death, stroke, renal failure, or new/worsening heart failure. It was not linked to severe adverse effects. |
Source: Jesper Kjaergaard, et al. “Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.” Read article here.
